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ABSTRACT  
BACKGROUND Cardiac transthyretin amyloidosis (ATTR) is an increasingly recognized cause 
of heart failure. Cardiac magnetic resonance (CMR), with late gadolinium enhancement (LGE) 
and T1 mapping, is emerging as a reference standard for diagnosis and characterization of 
cardiac amyloid.  
OBJECTIVES We used CMR with extracellular volume fraction (ECV) measurement to 
characterize cardiac involvement in relation to outcome in ATTR. 
METHODS Subjects comprised 263 patients with cardiac ATTR corroborated by grade 2 to 3 
99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) cardiac uptake, 17 with 
suspected cardiac ATTR (grade 1 99mTc-DPD), and 12 asymptomatic individuals with 
amyloidogenic transthyretin (TTR) mutations. Fifty patients with cardiac amyloid light-chain 
(AL) amyloidosis acted as disease comparators.  
RESULTS Unlike AL amyloidosis, asymmetric septal left ventricular hypertrophy (LVH) was 
present in 79% of patients with ATTR (70% sigmoid septum and 30% reverse septal contour), 
while symmetric LVH was present in 18%, and 3% had no LVH. In patients with cardiac 
amyloidosis, the pattern of LGE was always typical for amyloidosis (29% subendocardial, 71% 
transmural) including right ventricular LGE (96%). During follow-up (19 ± 14 months), 65 
patients died. ECV independently correlated with mortality and remained independent after 
adjustment for age, N-terminal pro-B-type natriuretic peptide, ejection fraction, E/E’, and left 
ventricular mass (hazard ratio: 1.164; 95% confidence interval: 1.066 to 1.271; p < 0.01). 
CONCLUSIONS Asymmetric hypertrophy, traditionally associated with hypertrophic 
cardiomyopathy, was the commonest pattern of ventricular remodeling in ATTR. LGE imaging 
was typical in all patients with cardiac ATTR. ECV correlated with amyloid burden and was an 
independent prognostic factor for survival in this cohort of patients. 
 
CONDENSED ABSTRACT: Cardiac transthyretin amyloidosis (ATTR) is an under-recognized 
cause of heart failure. CMR has emerged as the gold standard for diagnosis and characterization 
of cardiac amyloidosis. We used CMR with extracellular volume fraction (ECV) measurement to 
characterize cardiac involvement in relation to outcome in ATTR amyloidosis. Asymmetric 
hypertrophy, traditionally associated with hypertrophic cardiomyopathy, is the commonest 
pattern of ventricular remodeling in ATTR amyloidosis. LGE imaging is typical in all patients 
with cardiac ATTR amyloidosis. ECV correlates with amyloid burden and is an independent 
prognostic factor for survival in ATTR amyloid cardiomyopathy. 
 
KEY WORDS ATTR, extracellular volume fraction, late gadolinium enhancement, left 
ventricular hypertrophy, N-terminal pro-B-type natriuretic peptide 
 
 
ABBREVIATIONS AND ACRONYMS 
ATTR = transthyretin amyloidosis 
ATTRm = hereditary transthyretin amyloidosis 
CMR = cardiac magnetic resonance 
ECV = extracellular volume fraction 
LGE = late gadolinium enhancement 
LVH = left ventricular hypertrophy 
NT-proBNP = N-terminal pro-B-type natriuretic peptide 
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RV = right ventricle 
99m Tc-DPD = 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid 
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Cardiac transthyretin amyloidosis (ATTR) is a progressive and fatal form of amyloidosis caused 
by extracellular deposition of amyloid fibrils from liver-derived transthyretin (TTR) (1). ATTR 
may be hereditary, in which genetic variants of TTR are implicated and are associated with the 
overlapping syndromes of familial amyloid cardiomyopathy and familial amyloid 
polyneuropathy, or it may be sporadic, associated with deposition of wild-type transthyretin as 
amyloid. The latter predominantly involves the hearts of older individuals and the disorder is 
also known as senile systemic amyloidosis. At autopsy, cardiac ATTR amyloid deposition can be 
remarkably common, present in 8% to 16% of individuals older than 80 years (2). Conversely, 
cardiac ATTR is rarely diagnosed during life, but greater awareness and better imaging methods 
have increased its recognition lately among elderly patients with left ventricular hypertrophy 
(LVH) and in specific at-risk ethnic populations (3). 
Diagnosing cardiac ATTR amyloidosis is challenging. A suggestive constellation of 
electrocardiography, echocardiography, and biomarker findings are present in advanced disease, 
but interpretation may be confounded by common comorbidities such as hypertensive heart 
disease, diabetes, diastolic dysfunction, and renal disease (4-6). Bone tracer scintigraphy, using 
99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD), 99mTc-pyrophosphate 
(99mTc-PYP), and 99mTc-hydroxymethylene diphosphonate (99mTc-HMDP), has recently emerged 
as a sensitive tool for the identification of cardiac ATTR (7-9). However, this nuclear medicine 
method is typically only performed to confirm ATTR when a clinical suspicion exists, as it does 
not provide information on any of the other differentials of LVH, cardiac morphology, or 
function, and is semi-quantitative only (10), a limitation given the development of therapies able 
to stop or remove cardiac amyloid deposits (9,11). 
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In the last decade, cardiac magnetic resonance (CMR) has emerged as a robust imaging 
technique that provides detailed information about the presence, location, and distribution of 
hypertrophy, as well as visualization of cardiac amyloid infiltration with late gadolinium 
enhancement (LGE) imaging and measurement of cardiac amyloid burden with T1 mapping and 
extracellular volume (ECV) (12-18). One retrospective study in patients with cardiac 
amyloidosis (n = 51) suggested that a high proportion of patients have morphological phenotypes 
that differ from the classical description of concentric symmetric hypertrophy (19) but the 
amyloidosis type was not specified. No study has assessed the morphology in a large cohort of 
patients with ATTR. ECV has been shown to be an important marker of prognosis in patients 
with amyloid light-chain (AL) amyloidosis, but its prognostic significance has never been 
assessed in patients with ATTR. 
The aim of this study was to examine the CMR morphological phenotypes and tissue 
characterization findings in ATTR, to correlate these with clinical outcomes, and compare these 
findings with AL amyloidosis. 
 
METHODS 
Ethical approval was granted by the University College London/University College London 
Hospitals Joint Committees on the Ethics of Human Research Committee and all participants 
provided written informed consent. 
A total of 342 subjects were prospectively recruited between 2011 and 2015. The study 
population underwent comprehensive clinical evaluation and follow-up at the National 
Amyloidosis Centre, London, and comprised the 3 groups described below. Patients were 
systematically followed-up until October 4, 2016, the date of censor. 
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Cardiac ATTR was defined as the combination of symptoms with an echocardiogram 
consistent with or suggestive of cardiac amyloidosis, a grade 2 or 3 cardiac uptake on 99mTc-
DPD scintigraphy in the absence of a monoclonal gammopathy, or, in the presence of 
monoclonal gammopathy, a cardiac biopsy positive for TTR (9). Suspected cardiac ATTR was 
defined by grade 1 cardiac uptake on 99mTc-DPD scintigraphy in the absence of a monoclonal 
gammopathy. All subjects underwent sequencing of exons 2, 3, and 4 of the TTR gene. 
We recruited 263 consecutive patients (227 male; age 74 ± 9 years) with cardiac ATTR 
and 17 with suspected cardiac ATTR. 
TTR gene mutation carriers were defined as individuals with no evidence of clinical 
disease (no cardiac uptake on 99mTc-DPD scintigraphy and normal echocardiography, CMR, N-
terminal pro-B-type natriuretic peptide [NT-proBNP], and troponin T). Twelve TTR gene 
mutations carriers were recruited (4 male; age 47 ± 11 years). 
Cardiac AL amyloidosis was determined on the basis of international consensus criteria 
(20), and 50 consecutive patients with cardiac AL amyloidosis (37 male; age 63 ± 10 years) were 
recruited as a comparator group.  
Subjects with contraindications to CMR included a glomerular filtration rate <30 ml/min.  
CMR PROTOCOL. All participants underwent standard CMR on a 1.5-T clinical scanner. A 
standard volume and LGE study was performed. The gadolinium-based contrast agent used was 
0.1 mmol/kg of gadoterate meglumine. LGE imaging was acquired using magnitude 
reconstruction in all patients and phase-sensitive inversion recovery reconstruction (PSIR) in 
82% of patients. For native T1 and post-contrast mapping, basal and mid-ventricular short-axis 
and 4-chamber long-axis images were acquired using the modified look-locker inversion 
recovery (MOLLI) or shortened MOLLI sequence after regional shimming, as previously 
7 
described (21). After the bolus of gadoterate meglumine and standard LGE imaging (standard 
fast low-angle shot inversion recovery or balanced steady state free precession sequence with 
magnitude reconstruction and PSIR reconstruction), the T1 measurement was repeated with the 
MOLLI or shortened MOLLI sequence (22). In 17 patients with ATTR, post-contrast T1 map 
acquisition was not performed; 5 patients requested to terminate the scan early and 12 had 
claustrophobia. 
CMR IMAGE ANALYSIS. All CMR images and maps were analyzed offline. The presence of 
LVH was defined as increased left ventricular (LV) mass based on age- and sex-indexed 
reference values. Asymmetric septal hypertrophy was defined as the ratio between the septal and 
posterior wall >1.5 (19). Asymmetric septal hypertrophy comprised, in turn, 2 different patterns: 
1) sigmoid septum, with the septum being concave to the LV cavity and a prominent basal septal 
bulge; and 2) reverse septal contour with an abnormal convexity of the septum toward the LV 
cavity (23,24). The ratio between the septal and posterior wall ≤1.5 and increased mass was 
considered symmetric concentric LVH. 
T1 measurement was performed by drawing a region of interest in the basal to mid 
septum of the appropriate 4-chamber map. For ECV measurement, a single region of interest was 
drawn in each of the 4 required areas: myocardial T1 estimates (basal to mid septum in 4-
chamber map) and blood T1 estimates (LV cavity blood pool in 4 chamber map, avoiding the 
papillary muscles) before and after contrast administration. Hematocrit was measured in all 
subjects immediately before each CMR study. ECV was calculated as myocardial ECV = (1-
hematocrit) x (ΔR1myocardium/ΔR1blood), where R1 = 1/T1. 
Before our adoption of PSIR for all amyloidosis patients, because myocardial nulling can 
be difficult in the presence of amyloid, any confusion with magnitude reconstruction images was 
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resolved by selecting the images that most matched the post-contrast T1 maps, with “bright” 
LGE expected to correlate with areas of the lowest postcontrast T1 (i.e., the highest gadolinium 
concentration, the highest interstitial expansion). 
The LGE pattern was classified into 3 groups according to the degree of transmurality: 
group 1, no LGE; group 2, subendocardial LGE (when there was global subendocardial but no 
transmural LGE); and group 3, transmural LGE (when the LGE was extending transmurally). 
Thus, a patient with basal transmural LGE but apical subendocardial LGE would be classified as 
transmural LGE (25). 
99MTC-DPD SCINTIGRAPHY. Subjects were scanned using hybrid single-photon emission 
computed tomography (SPECT) computed tomography (CT) gamma cameras following 
administration of 700 MBq of intravenously-injected 99mTc-DPD. Whole-body planar images 
were acquired after 3 h, followed by SPECT of the heart coupled with a low-dose, noncontrast 
CT scan as previously described (26). Gated and nongated cardiac SPECT reconstruction and 
SPECT-CT image fusion was performed on the Xeleris workstation (GE Healthcare, 
Wauwatosa, Wisconsin). Cardiac retention of 99mTc-DPD was scored visually according to the 
grading devised by Perugini et al. (27) using the following grading system: grade 0, absent 
cardiac uptake; grade 1, mild cardiac uptake less than bone; grade 2, moderate cardiac uptake 
equal or greater than bone; and grade 3, intense cardiac uptake associated with substantial 
reduction or loss of bone signal. 
STATISTICAL ANALYSIS. Statistical analysis was performed using IBM SPSS Statistics 
version 22 (IBM, Armonk, New York). All continuous variables were normally distributed 
(Shapiro-Wilk test), other than NT-proBNP, which was natural log transformed for bivariate 
testing. These are presented as mean ± SD with non-natural log transformed NT-proBNP 
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presented as median and interquartile range. Comparisons between groups were performed by 1-
way analysis of variance with post hoc Bonferroni correction. The chi-square test or Fisher exact 
test was used to compare categorical data as appropriate. Correlations between parameters were 
assessed using Pearson (r) or Spearman’s rho. Statistical significance was defined as p < 0.05. 
Survival was evaluated using Cox proportional hazards regression analysis, providing 
estimated hazard ratios (HR) with 95% confidence intervals (CI) and Kaplan-Meier curves. HRs 
were estimated for pre-defined increments or decrements in the variables based on clinically 
relevant changes and/or published normative data guidelines. All variables were selected a priori 
for clinical relevance: ECV as marker of amyloid infiltration; ejection fraction for systolic 
function; E/E’ for diastolic function; LV mass for structural changes; and NT-proBNP as blood 
biomarker. A multivariable model was used to investigate factors associated with overall 
survival. 
 
RESULTS 
The details of the 342 subjects are shown in Table 1. Of the 263 consecutive patients with 
ATTR, 168 had wild-type ATTR and 95 hereditary ATTR (ATTRm). Of the 17 patients with 
suspected cardiac ATTR, 9 had wild-type TTR gene sequence and 8 had amyloidogenic TTR 
gene mutations. The TTR mutations in cardiac amyloidosis were: V122I (n = 49); T60A (n = 26); 
V30M (n = 8); S77Y (n = 2); and E54G, E54L, E89K, D38Y, D39V, E89K, V20I, F44L, G89L 
and L12P in 1 case each. The mutations among the possible cardiac amyloidosis subjects were: 
S77Y (n = 3) and V30M, I107F, E54G, G47V, and I84S in 1 case each. Finally, the mutations 
among the mutation carriers were: T60A (n = 6); V30M (n = 5); and S77Y (n = 1). 
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MORPHOLOGICAL PHENOTYPES. Asymmetric septal hypertrophy, defined as the ratio 
between the septal and posterior wall >1.5 (19,28), was the most common form of ventricular 
remodeling in ATTR, being present in 79% of patients with cardiac ATTR. The pattern of 
asymmetric septal hypertrophy was divided into the morphological subtypes of sigmoid septum 
(55%) and reverse septal contour (24%). Symmetric concentric LVH, considered typical for 
amyloidosis, was present in only 18% of patients with ATTR (Figure 1). There were no 
differences in the prevalence of the different morphological phenotypes in wild-type ATTR and 
ATTRm (sigmoid septal 53% vs. 60%, reverse septal curvature 25% vs. 20%, and symmetric 
concentric LVH 19% vs. 18%, respectively). Seven patients (3%) with cardiac ATTR 
amyloidosis (grade 2 or 3 cardiac uptake on 99mTc-DPD scintigraphy) had no LVH (2 with 
ATTRm and 5 with wild-type ATTR). 
Prevalence of asymmetric septal hypertrophy was significantly higher in ATTR 
compared to patients with cardiac AL amyloidosis (79% vs. 14%; p < 0.001), where the most 
common form of ventricular remodeling was symmetric concentric LVH (34 patients [68%]), 
followed by asymmetric pattern with sigmoid septal contour in 7 patients (14%). The asymmetric 
pattern with reverse septal contour was not found in the AL amyloidosis cohort. Nine patients 
(18%) with cardiac AL amyloidosis had no LVH. 
TISSUE CHARACTERIZATION FINDINGS. In patients with cardiac amyloidosis, LGE was 
always present and the pattern of LGE was typical for amyloidosis, being diffuse subendocardial 
LGE in 29% of patients and transmural LGE in 71% (Figure 2). Right ventricular (RV) LGE 
was extremely frequent, being present in 96% of patients. There was no difference in LGE 
prevalence between wild-type ATTR and ATTRm (transmural LGE 71% vs. 72% and 
subendocardial LGE 29% vs. 28%; p > 0.05 for both). As previously reported, the prevalence of 
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transmural LGE and RV LGE was significantly higher in ATTR compared to AL (transmural 
LGE 71% vs. 50% and RV LGE 96% vs. 77%; p < 0.01 for both). In this population, transmural 
LGE was not associated with a worse prognosis than subendocardial LGE (p = 0.327). 
Patients with suspected cardiac amyloidosis (17 patients with grade 1 uptake on 99mTc-
DPD) did not show characteristic LGE of amyloidosis with the notable exception of patients with 
the Se77Tyr variant (3 patients in our cohort with 99mTc-DPD grade 1). The rest of the patients 
showed no LGE (n = 10), subendocardial LGE with ischemic pattern (n = 2), and mid wall LGE 
in the basal infero-lateral wall (n = 2) (Online Figures 1 and 2). The 3 patients with Se77Tyr 
and 99mTc-DPD grade 1 had typical LGE pattern (1 presented subendocardial LGE and 2 
transmural LGE). The clinical, morphological, and functional features of these 3 patients were 
also in keeping with cardiac amyloidosis on echocardiogram, ECV measurements, and 
biomarkers (Figure 3), suggesting that they have less DPD uptake than they should given the 
amyloid burden.  
 There was good correlation between ECV and cardiac uptake on 99mTc-DPD scintigraphy 
(r = 0.533; p < 0.05). Except for patients with the Se77Tyr variant and grade 1 on 99mTc-DPD 
scintigraphy, ECV discriminated patients with ATTR with cardiac amyloidosis from patients 
with no or possible cardiac involvement (Figure 4). ECV was not significantly different in 
ATTRm compared to wild-type ATTR. When ECV was compared across the different mutations 
in patients with cardiac ATTR, patients with V30M had a significantly lower ECV than patients 
with wild-type ATTR, T60A, and V122I (42 ± 10% vs. 59 ± 11%, 54 ± 15, and 64 ± 13%, 
respectively; all p < 0.05) and patients with V122I had significantly higher ECV than patients 
with V30M and T60A (65 ± 13% vs. 42 ± 10%, and 54 ± 15%, respectively; all p < 0.05) 
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AMYLOID BURDEN AND SURVIVAL. At follow-up (19 ± 14 months), 65 of 292 subjects 
had died (36 with wild-type ATTR and 29 with ATTRm). ECV predicted death in the overall 
population (HR: 1.144; 95% CI: 1.075 to 1.218; p < 0.001) and separately in the wild-type 
ATTR and ATTRm groups (p < 0.01 for both) (Figure 5). ECV remained significantly 
associated with mortality (HR: 1.164; 95% CI: 1.066 to 1.271; p < 0.01) in multivariable Cox 
models that included age, NT-proBNP, ejection fraction, E/E’, and LV mass index (troponin was 
not available in all patients) (Table 2). 
 
DISCUSSION 
In a prospective study at a single center, we describe here the specific morphological and tissue 
characteristics of ATTR cardiac amyloidosis using state-of-the-art imaging with CMR and 
identify what distinguishes it from AL and specific ATTR prognostic determinants. 
This study had 3 major findings (Central Illustration). First, the morphological 
phenotype of patients with ATTR differed from AL and the one traditionally described, with 
asymmetric LVH present in 79% of patients with ATTR amyloidosis versus 14% in AL 
amyloidosis. Reverse septal contour, classically associated with hypertrophic cardiomyopathy, 
was present in one-quarter of patients with ATTR. Additionally, LGE and ECV presented typical 
features in patients with ATTR, with very elevated ECV values and subendocardial or transmural 
LGE pattern. ECV correlated with cardiac uptake by 99mTc-DPD scintigraphy in all patients, 
except for those with the Se77Tyr mutation where the degree of cardiac uptake on 99mTc-DPD 
scintigraphy stood out as being disproportionately low compared to the severity of cardiac 
involvement assessed by functional, structural, and clinical parameters. Finally, ECV predicted 
death and remained independent after adjustment for known prognostic factors. 
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The LVH morphology in ATTR was surprising. The conventional view is that cardiac 
amyloidosis leads to symmetrically increased wall thickness. We suspect this happens due to 
several reasons. The literature is heavily weighted towards AL where the morphology is mainly 
concentric, as ATTR could until recently only be diagnosed definitively by endomyocardial 
biopsy. Furthermore, patients with ATTR are typically elderly, and increased aorto-septal 
angulation could confound ascertainment, particularly by echocardiography. In addition, a focus 
on nomenclature, as to whether the wall thickening should be called hypertrophy or not, might 
have prevented additional scrutiny. Looking further, we also note that the asymmetric pattern 
with reverse septal contour was not found among the cardiac AL patients. This observation has 
important immediate diagnostic implications, as the association between amyloidosis and 
symmetric septal hypertrophy could play an important role in the misdiagnosis of ATTR. One 
possibility that could explain why this pattern occurs is related to differential rates of effective 
cell hypertrophy in AL versus ATTR. Our prior work highlighted that in ATTR, total cell mass 
increased, whereas it remained the same in AL (29). It is possible that while infiltration was 
global, a triggered myocyte response differentially induced septal hypertrophy. Another 
possibility is that AL patients died before their total infiltration achieved the levels found in 
ATTR, so they were unable to get to the reverse septal contour stage. 
We found that in all patients with cardiac ATTR, the pattern of late gadolinium 
enhancement was always typical of cardiac amyloidosis, with a subendocardial or transmural 
LGE pattern (25,30). Subendocardial LGE was found in 29% and the remainder (71%) showed 
transmural LGE. RV LGE was present in 96% of patients. This confirmed previous reports on 
the high prevalence of transmural LGE and RV LGE in ATTR (31), but it also highlighted the 
important role that CMR could have in diagnosing this disease. The typical appearance of LGE 
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in patients with cardiac ATTR with subendocardial or transmural LGE has the potential to 
revolutionize the diagnostic pathway of this disease, as CMR is currently the diagnostic 
reference standard for the differential diagnosis of cardiomyopathies with hypertrophic 
phenotype. 
With the exception of patients with the Se77Tyr variant, none of the patients with 
suspected rather than proven cardiac ATTR (defined as grade 1 cardiac uptake on 99mTc-DPD 
scintigraphy) showed LVH, typical LGE, or very elevated ECV (although a mild elevation in 
ECV was noted). In patients with the Se77Tyr variant and grade 1 cardiac uptake on 99mTc-DPD 
scintigraphy, CMR showed typical features of cardiac involvement with LVH, characteristic 
LGE, and increased ECV. As assessed by functional, structural, and clinical parameters, there 
was good agreement between the CMR characterization of the degree of cardiac involvement 
and the echocardiographic and clinical features, while a discrepancy was observed with the 
degree of cardiac uptake on 99mTc-DPD scintigraphy that had been disproportionately low 
(Figure 3). The mechanism for this phenomenon remains unknown, but raises the possibility of 
the degree of cardiac uptake being variant dependent. 
Extracellular volume is the first noninvasive method for quantifying the cardiac 
interstitium, and several papers have shown correlation with markers of disease severity in both 
types of cardiac amyloidosis (16,32,33). When ECV was compared across the different 
mutations in patients with cardiac ATTR, patients with V30M had a significantly lower ECV 
than patients with wild-type ATTR, T60A, and V122I. The disease associated with the TTR 
V30M variant usually causes a predominant sensorimotor peripheral neuropathy and autonomic 
neuropathy. Although cardiac amyloidosis might occur in older patients with this TTR variant, 
the vast majority of patients have minor degrees of cardiac involvement or, in younger affected 
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individuals, none at all. Therefore, the lower ECV likely represents the different clinical 
phenotype of this variant compared with other variants that are characterized by predominantly 
cardiac features (even though the neurological phenotype can coexist). The prognostic value of 
ECV in AL amyloidosis was recently shown (33) and here, for the first time, we have 
demonstrated that ECV adds incremental value over and above existing clinical markers in 
ATTR. ECV was predictive regardless of whether patients were presenting at diagnosis or years 
into the disease process, highlighting the potential use of the ECV to assess disease status 
throughout the course of disease progression. A spectrum of disease burden exists, ranging from 
small incidental deposits with no clinical consequence to very extensive deposits causing severe 
organ failure. LGE can confirm the diagnosis and divide patients with cardiac amyloidosis into 
groups that likely represent different stages of myocardial infiltration with the transmural pattern 
being associated with a higher ECV compared to the subendocardial one. ECV can measure the 
continuum of amyloid infiltration, enabling the clinician to fully characterize phenotypes, their 
stages of evolution, and the prognostic implication of amyloid deposition. The better prognostic 
ability of ECV compared to LGE likely springs from better discriminatory powers of ECV, 
which can measure the continuum of infiltration rather than a binary categorization. Some 
patients in the cohort had modest ECV increase without evidence of cardiac involvement by 
echocardiogram, LGE, or blood biomarkers; suggesting that, like in AL, ECV can detect early 
cardiac involvement (29). The presence of low grade disease was also confirmed by a low degree 
of cardiac uptake on the 99mTc-DPD scintigraphy that seemed to show a similar sensitivity. 
STUDY LIMITATIONS. This study has several limitations. We used the proposed noninvasive 
criteria for ATTR (9), meaning cardiac biopsy was performed only in a minority of patients. Two 
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different T1 mapping techniques were used during the period in which these patients were 
recruited and a wide range of TTR mutations were included in the analysis. 
 
CONCLUSIONS The morphological phenotype of patients with ATTR was different from the 
one traditionally described: asymmetric LVH was the commonest pattern of ventricular 
hypertrophy in cardiac ATTR, with reverse septal contour, classically associated with 
hypertrophic cardiomyopathy, being present in one-quarter of patients with ATTR. LGE and 
ECV presented typical features in patients with ATTR amyloidosis, with very elevated ECV 
values and subendocardial or transmural LGE pattern.  ECV, a noninvasive quantification of the 
cardiac amyloid burden, predicted death and remained an independent predictor of prognosis 
after adjustment for known prognostic factors. 
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PERSPECTIVES: 
 
COMPETENCY IN MEDICAL KNOWLEDGE: The morphological phenotype of patients 
with ATTR is most commonly characterized by asymmetric LVH. LGE and high ECV fraction 
are typical features on CMR. Measurement of ECV by this method is a noninvasive index of 
cardiac amyloid burden and an independent predictor of prognosis. 
TRANSLATIONAL OUTLOOK: Future characterization of patients with ATTR by CMR may 
identify earlier features of the disease, which is an under-recognized cause of heart failure in the 
elderly. 
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FIGURE LEGENDS 
CENTRAL ILLUSTRATION CMR in ATTR  
In this study, cardiac magnetic resonance (CMR) with extracellular volume (ECV) was used to 
characterize cardiac involvement as it related to outcomes in cardiac transthyretin amyloidosis 
(ATTR). The relationship between late gadolinium enhancement (LGE) patterns and ECV 
showed a typical correlation of very high ECV values and subendocardial or transmural LGE. 
Asymmetric septal left ventricular hypertrophy (LVH) was present in 79% of patients with 
ATTR, more than 5 times higher than that seen in patients with cardiac amyloid light-chain 
amyloidosis. In patients with ATTR, ECV was independently correlated with mortality. 
 
FIGURE 1 Morphology Patterns in ATTR  
In 4 patients with cardiac transthyretin amyloidosis (ATTR), 4-chamber cine image in diastole 
and corresponding late gadolinium enhancement (LGE) illustrate asymmetric hypertrophy with 
sigmoid septal contour and transmural LGE; asymmetric hypertrophy with reverse septal contour 
and transmural LGE; symmetric hypertrophy pattern and transmural LGE; and no left ventricular 
hypertrophy (LVH) and subendocardial LGE. 
 
FIGURE 2 LGE Patterns Correlating with T1 and ECV Measurements  
Images shown include 4-chamber cine, corresponding LGE image with phase sensitive 
reconstruction, native T1 maps, and extracellular volume (ECV) maps in 3 patients with ATTR. 
The patient with no LGE has normal native T1 and ECV maps; the patient with subendocardial 
LGE shows borderline T1 values and high ECV values; and in the patient with transmural LGE, 
23 
very high native T1 values and very high ECV values are seen. Other abbreviations as in Figure 
1. 
 
FIGURE 3 Patient with ATTR with Se77Tyr Variant  
This multidisciplinary workup of a patient with ATTR with an Se77Tyr variant displayed (A) a 
strain pattern characteristic of an infiltrative process; (B) a 4-chamber cine steady-state free 
precession image and corresponding LGE image showing transmural LGE; and (C) whole-body 
anterior 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc-DPD) scintigraphy and 
hybrid single-photon emission computed tomography-computed tomography showing Perugini 
grade 1 abnormal uptake. Other abbreviations as in Figure 1. 
 
FIGURE 4 ECV and Cardiac Uptake   
As seen in this correlation between ECV and grade of abnormal cardiac uptake on Tc-DPD 
scintigraphy, only patients with the Se77Tyr variant had high ECV measurements with grade 1 
abnormal uptake. Abbreviations as in Figures 2 and 3. 
  
FIGURE 5 Survival Analysis  
As seen via Kaplan-Meier curves, ECV was independently correlated with mortality in all 
patients with ATTR as well as those hereditary and wild-type ATTR. Abbreviations as in Figures 
1 and 2. 
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TABLE 1 Patient Characteristics 
 
 
All ATTR 
Subjects (n 
= 292) 
Tc-DPD 
Grade 0 
(n = 12) 
Tc-DPD 
Grade 1 
(n = 17) 
Tc-DPD 
Grade 2 
(n = 204) 
Tc-DPD 
Grade 3 
(n = 59) 
AL 
(n = 50) 
Age, yrs 72  11 47  11 70  14 75  8 72  11* 63  10† 
Comorbidities 
Diabetes mellitus 7 0 0 8 7 0† 
Hypertension 17 0 24 18 14 10† 
Ischemic heart 
disease 
10 0 18 13 2 10 
Biomarkers 
 
NT-proBNP, ng/l 1,886 
(576-
1,217) 
21 (10-31) 247 (47-
288) 
2,001 (690-
2,168) 
2,342 (741-
3,683)* 
1,886 
(575-
2,168) 
Echocardiographic parameters 
 
IVS, cm  1.61  
0.29 
0.95  
0.12 
1.12  
0.28 
1.65  0.22 1.72  
0.24* 
1.49  
0.18† 
LPW, cm 1.31  
0.25  
0.88  
0.11 
1.11  
0.27 
1.34  0.23 1.38  
0.23*  
1.24  
0.23† 
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LVEDD, cm 4.50  
1.77 
4.73  
0.54 
4.52  
0.58 
4.40  0.59 4.28  0.70 4.20  
0.55 
LA area, cm2 28.82  
6.20 
15.10  
5.35 
21.09  
4.59 
27.06  
5.74 
25.2  
5.63* 
22.78  
4.54† 
E wave, cm/s 0.84  
0.20 
0.79  
0.12 
0.75  
0.16 
0.85  0.19 0.84  
0.25* 
0.85  
0.21 
A wave, cm/s 0.50  
0.24 
0.67  
0.17 
0.73  
0.16 
0.47  0.23 0.46  
0.24* 
0.55  
0.28† 
E/A 2.92  
7.79 
1.23  
0.25 
1.05  
0.25 
2.88  5.52 4.12  
13.58 
1.84  
1.07 
Average E’, cm/s 0.10  
0.68 
0.10  
0.05 
0.09  
0.03 
0.14  0.06 0.25  1.52 0.06  
0.02 
E/E’ 16  8 13  18 10  4 16  6 19  9* 17  8 
E wave 
deceleration time, 
ms 
180  56 181 48 187  45 183  55 168  62 184  52 
2-dimensional 
GLS 
-11.6  4.6 -18.8  3.4 -17.7  5.0  -11.4  4.2 -8.8   2.8*  -11.3  4.6 
CMR parameters 
 
LV mass, g 244  77 114  37 162  76 252  64 264  89* 197  65† 
LV massi, g/cm
2 130  41 59  12 84  44 132  33 149  46* 103  30† 
26 
Maximal IVS, 
mm 
18  5 8  1 13  4 20  4 21  4* 17  4† 
LVEDV, ml 131  36 124  25 132  28 133  36 128  39 115  26† 
LVEDVi, ml/m
2 69  18 66  13 69 13 70  18 70  22 61  15† 
LVESV, ml 60.65  
30.77 
38.58  
12.24 
43.47  
22.92 
62.11  
30.41 
65.75  
33.41* 
44.66  
15.28† 
LVESVi, ml/m
2 32  16 20  6 23 13 32  15 36  18* 24  9† 
LVSV, ml 71  20 85  16 89  23 71  19 63  16* 70  20 
LVSVi, ml/m
2 38  10 45  8 45  11 37  10 36  8* 37  12 
LVEF, % 56  14 69  5 69 11 55  14 52  14* 61  11† 
RV mass, g 77  24 38  12 48  20 82  21 80  22* 63  16† 
RV massi, g/m
2 41  13 20  6 26  11 43  11 44  12* 33  8† 
RVEDV, ml 131  36 124  26 115  22 135  38 125  34 114  24† 
RVEDVi, ml/m
2 70  19 68  13 62  10 71  20 69  19 60  12† 
RVESV, ml 64  30 45  10 41  15 68  32 65  27* 54  19† 
RVESVi, ml/m
2 34  16 25  5 22  8 35  17 36  15* 28  10† 
RVSV, ml 67  19 80  18 74  15 68  19 58  17* 61  17† 
RVSVi, ml/m
2 36  10 43  9 40  8 36  10 32  9* 32  9† 
RVEF, % 53  13 64  3 65  10 52  13 49  12* 54  12 
LA area, cm2 31  8 22  4 25  6 33  9 29  5* 26  5† 
RA area, cm2 28  8 20  2 23  5 30  8 27  6* 25  6† 
27 
MAPSE, mm 8  3 14  2 11  3 7  2 6  2* 7  4 
TAPSE, mm 13  5 23  3 22  5 12  4 11  4* 14  6† 
ECV, % 59  13 29  3 39  12 59  10 66  10* 53  8† 
Values are mean ± SD, %, or median (interquartile range). 
*p < 0.05 for trend (1-way analysis of variance) in patients with transthyretin amyloidosis 
(ATTR) across different grades of uptake by Tc-DPD scintigraphy. 
†p < 0.05 AL versus ATTR (Tc-DPD grade 2 and 3). 
AL = amyloid light-chain amyloidosis; ECV = extracellular volume; GLS = global longitudinal 
strain; IVS = interventricular septum; LA = left atrium; LPW = left posterior wall; LV = left 
ventricular; LVEDD = left ventricular end-diastolic diameter; LVEDV = left ventricular end-
diastolic volume; LVEF = left ventricular ejection fraction; LVESV = left ventricular end 
systolic volume; LVSV = left ventricular stroke volume; MAPSE = mitral annular plane systolic 
excursion; NT-proBNP = N-terminal pro-B-type natriuretic peptide; RA = right atrium; RV = 
right ventricular; RVEDV = right ventricular end-diastolic volume; RVEF = right ventricular 
ejection fraction; RVESV = right ventricular end-systolic volume; RVSV = right ventricular 
stroke volume; TAPSE = tricuspid annular plane systolic excursion; Tc-DPD = 99mTc-3,3-
diphosphono-1,2-propanodicarboxylic acid scintigraphy.  
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TABLE 2 Multivariable Analysis of Mortality Risk in Patients with ATTR  
 HR (95% CI) p Value 
Age 1.059 (1.016-1.013) <0.01 
LV mass, each 10 g 
increase 
0.941 (0.853-1.039) 0.229 
LVEF, each 3% 
increase 
0.986 (0.916-1.060) 0.699 
NT-proBNP, each 
100-pmol/l increase 
1.016 (1.005-1.027) <0.01 
E/E’, each 1-unit 
increase 
0.996 (0.949-1.045) 0.873 
ECV, each 3% 
increase 
1.164 (1.066-1.271) <0.01 
CI = confidence interval; HR = hazard ratio; other abbreviations as in Table 1.  
